Targeted Treatment of Refractory PNET Arising from An Immature Teratoma
with Crizotinib Leading to a Sustained Response
- Benjamin Snyder,
- Alex Lion,
- Amy Helvie,
- Mark Marshall,
- Michael Ferguson
Benjamin Snyder
Indiana University School of Medicine
Corresponding Author:snyderbm@iu.edu
Author ProfileAbstract
Here we present a case of metastatic PNET which arose from an immature
teratoma that was refractory to standard Ewing sarcoma chemotherapy.
This PNET was determined to have elevated levels of ALK protein via IHC.
The patient was treated with crizotinib on a palliative basis with a
sustained response.13 Sep 2022Submitted to Clinical Case Reports 14 Sep 2022Submission Checks Completed
14 Sep 2022Assigned to Editor
19 Sep 2022Reviewer(s) Assigned
25 Sep 2022Review(s) Completed, Editorial Evaluation Pending
14 Oct 2022Editorial Decision: Revise Minor
17 Nov 20221st Revision Received
18 Nov 2022Submission Checks Completed
18 Nov 2022Assigned to Editor
18 Nov 2022Review(s) Completed, Editorial Evaluation Pending
05 Dec 2022Editorial Decision: Accept
